A 34-year-old female diagnosed with fibromyalgia, generalized anxiety disorder, and depression is currently taking several psychotropic medications, including alprazolam, duloxetine, pregabalin, and hydrocodone/acetaminophen. The patient continues to have some residual pain, anxiety, and mood symptoms. The PMHNP is considering simplifying the patient's regimen and plans to discontinue the least efficacious medication for the patient's disorders. Which of the following medications should be discontinued?

A. Alprazolam: Alprazolam is a short-acting benzodiazepine primarily used for acute anxiety. Long-term use is generally discouraged due to risks of dependence, tolerance, and cognitive impairment. It has limited efficacy for chronic anxiety and fibromyalgia-related pain, making it the most appropriate medication to discontinue. B. Hydrocodone/acetaminophen: This combination provides analgesic relief for fibromyalgia-related pain. While caution is needed for long-term opioid use, it still addresses residual pain that the patient reports, so discontinuation may worsen symptom control. C. Duloxetine: Duloxetine is a serotonin-norepinephrine reuptake inhibitor that effectively treats depression, anxiety, and neuropathic pain associated with fibromyalgia. Discontinuing it could exacerbate mood and pain symptoms, so it should be maintained. D. Pregabalin: Pregabalin is FDA-approved for fibromyalgia and helps reduce neuropathic pain and anxiety symptoms. It remains a key component of the patient’s pain management regimen, so discontinuation is not advisable at this stage.